Sangam Health Care Products Ltd

Dematerialisation outcome

• Securities received for dematerialisation during the quarter were confirmed to the depositories.
• Securities dematerialised have been listed on the stock exchange where the earlier issued securities are listed.
• Dematerialisation certificates were mutilated and cancelled after verification; depository name substituted in register of members within 30 days.

AGM Details

• Date and time: 30 September 2026, 9:00 AM.
• Mode: Physical meeting with e-voting facility.
• Venue: Survey No.182, Yellampet Village, Medchal District, Telangana.
• Quorum present; meeting concluded at 9:45 AM.
• Electronic voting available; ballots conducted at meeting.

Key Resolutions

• Adoption of Audited financial statements and related reports — Passed.
• Reappointment of Sai Balaji Krishna Teja Addepalli by rotation — Passed.
• Continuation of Padma Ghanakota as Non-Executive Non-Independent Director — Passed.
• Reappointment of Bhagat Reddy Dundumulla as Managing Director — Passed.

Voting Results

• All four resolutions passed; 100% favourable votes on ballots.
• Adoption of financials — Passed.
• Director rotation — Passed.
• Continuance of Padma Ghanakota — Passed.
• MD reappointment — Passed.

Director Changes

• Sai Balaji Krishna Teja Addepalli reappointed by rotation.
• Padma Ghanakota continuation as NED.
• Bhagat Reddy Dundumulla continued as Managing Director.

Other Governance Details

• Scrutinizer appointed to supervise e-voting.

Sangam Health Care Products Ltd: Trading Window closed from 1 October 2026 and will re-open after completion of 48 hours from the declaration of Un Audited Financial Results for the quarter and half year ending 30.09.2026

Overall Compliance Status

• Partial compliance; material gaps under Reg 47(1), Reg 25, Reg 17(10).
• Secretarial Standards non-compliance noted; board evaluation not conducted.
• Past-year non-submission of secretarial report noted.

Key Non-Compliances

• Reg 47(1): Financial results not published in newspapers; filed with exchange.
• Reg 25: Declarations of independence from Independent Directors not furnished.
• Reg 17(10): Board/committee annual performance evaluation not conducted.
• SS non-compliance: Secretarial Standards not followed.
• Past-year non-submission of annual secretarial report.

Remedial Actions

• Results filed with stock exchange and uploaded on website.
• Independent Directors confirmed; independence declarations to be collected timely.
• Board evaluation to be conducted in current financial year.
• Past non-submission issue being addressed.

Board and Committee Composition

• Directors not disqualified; board composition structurally compliant.
• Board evaluation pending; governance process under review.

Website and Disclosure Practices

• Website functional; required disclosures uploaded; links accurate.
• Regulatory disclosures on website timely and accessible.

Subsidiary Compliance

• Identification and review of material subsidiaries not applicable.

Regulatory Actions

• No actions by SEBI or stock exchanges reported.

Special Situations

• Not applicable; no insolvency, liquidation, or exemption status.

Book closure & AGM details

• Register of Members and share transfer books closed from 24 Sep 2026 to 30 Sep 2026 (inclusive).
• Annual General Meeting scheduled for 30 Sep 2026 at 9:00 AM at registered office.
• Regulation 42 of SEBI LODR cited for book closure requirements.

AGM Details

• Date and venue: 30 September 2026, 9:00 AM, at registered office.
• Mode: physical meeting; book closure 24 Sep to 30 Sep 2026 (inclusive).
• Notice dispatched to shareholders on 8 September 2026.

Key Resolutions

• Ordinary: Adoption of Audited Balance Sheet, P&L, and cash flow for year ended 31 March 2026.
• Ordinary: Reappointment of A. Sai Balaji Krishna Teja as director.
• Ordinary: Continuation of Padma Ghanakota as Non-Executive, Non-Independent Director.
• Special: Re-appointment of Bhagat Reddy Dundumulla as Managing Director for five years.

Voting Results

• Voting results not disclosed in the filing.

Dividend

• Dividend: Directors decided not to recommend any dividend for 2025-26.

Director Changes

• Reappointment of A. Sai Balaji Krishna Teja as Non-Executive Director.
• Continuation of Padma Ghanakota as Non-Executive, Non-Independent Director.
• Re-appointment of Bhagat Reddy Dundumulla as Managing Director for five years.

Auditors

• Statutory auditors: M/s M.M. Reddy & Co. appointed for five years, subject to member approval.
• Internal auditors: M/s K. R. Shekhar & Co. re-appointed for 2026-27.
• Secretarial auditor: Chakravarthy & Associates appointed; details in the annual report.
• Auditors’ remuneration: statutory audit fees Rs 2.34 lakhs.

Material Related Party Transactions

• Balagopal: unsecured loan outstanding closing balance 574.01 lakh.
• Padma Ghanakota: loans/advances asset closing balance 31.72 lakh.
• Sri Siri Constructions: unsecured loans closing balance 1,279.99 lakh.
• Total related party borrowings: 1,885.72 lakh.

Other Material Approvals

• Listing on BSE restored by Securities Appellate Tribunal on 17.04.2025.
• Company under BSE suspension; management pursuing revocation.

Financial snapshot

• Revenue from operations: 1,123.33 lakh in FY2025-26.
• Net profit after tax: 5.33 lakh in FY2025-26.
• YoY: FY2024-25 turnover 1,245.96 lakh; PAT 44.97.
• Profit before tax 20.71 lakh; depreciation 5.64; finance costs 0.91.
• Tax expense 5.38; deferred tax 10.00.
• Net cash from operating activities 2.58; investing -2.39; financing -4.83.
• Earnings per share: Basic 0.04; Diluted 0.04.
• Dividend for FY2025-26: not declared.

Operations and capacity

• IV sets capacity raised to 40 million per annum.
• Disposable syringes capacity 264 million; needles 135 million.
• Core products: IV sets, syringes, needles; expansion ongoing.
• No change in business lines during FY25-26.

Capital structure and liquidity

• Non-current borrowings: Rs 2,193.34 lakh; current borrowings: nil.
• Unsecured loans from individuals: Rs 2,171.89 lakh.
• State govt tax deferral loan: Rs 21.45 lakh.
• Debt/equity ratio: (1.57); current ratio: 0.79.

Governance and board

• Mr. Bhagat Reddy Dundumulla reappointed as MD for five years from 7 Sep 2026.
• Mrs. Padma Ghanakota to continue as Non-Executive, non-independent.
• Ms. S. Vijayagowri Satya Bhavani appointed CFO from 24 Feb 2026.
• AGM set for 30 Sep 2026; e-voting details disclosed.
• Board meetings held: four; Audit/NRC/Stakeholders committees in place.

Audits, compliance and governance notes

• Statutory auditors: M. M. Reddy & Co; internal auditors: K. R. Shekhar & Co.
• Secretarial audit flagged multiple observations; actions in progress.
• CEO/CFO certificate and code of conduct filed; compliance at website.

Shareholding and market status

• Promoter group holds about 74% of equity as of 31 Mar 2026.
• Top holders include Addepalli Balagopal (20.19%), DVS Sharma (16.82%), Ram Ramana (15.18%), Padma Ghanakota (13.46%), Boin Medica (8.35%).
• Public holding ~26%; Dematerialization largely through CDSL (75.52%).
• Trading suspended on BSE; SAT directed reinstatement in 2025; status under review.

Risk and outlook

• Price controls and regulatory changes risk margins; expansion planned to drive revenue.
• Industry competition intensifies; focus on quality and efficiency.

Other notable items

• AGM and notice available on company website; e-communications encouraged.
• Management expects near-term improvement as expansion investments mature.

MD re-appointment

• Re-appointed Bhagat Reddy Dundumulla as Managing Director for five years from 05 Sep 2026.
• Subject to shareholders' approval at the ensuing AGM.
• Profile: 12 years’ experience in manufacturing IV sets and medical disposables.
• Not related to any other director.
• Shareholding: 200,000 shares.
• Not debarred by SEBI or other authorities.

Director re-appointment: Padma Ghanakota

• Recommendation for reappointment of Padma Ghanakota (DIN 07078176) who retires by rotation.
• Subject to approval by members at the AGM.

Meeting Details

• Date, time, and venue not disclosed in this chunk.